5-HT5A receptor

From Wikipedia, the free encyclopedia
  (Redirected from 5-HT5 receptor)
Jump to: navigation, search
Aliases HTR5A, 5-HT5A, 5-HT5A receptor, 5-hydroxytryptamine receptor 5A
External IDs MGI: 96283 HomoloGene: 22461 GeneCards: HTR5A
Gene location (Human)
Chromosome 7 (human)
Chr. Chromosome 7 (human)[1]
Chromosome 7 (human)
Genomic location for HTR5A
Genomic location for HTR5A
Band No data available Start 155,070,324 bp[1]
End 155,085,749 bp[1]
RNA expression pattern
PBB GE HTR5A 221362 at fs.png
More reference expression data
Species Human Mouse
RefSeq (mRNA)



RefSeq (protein)



Location (UCSC) Chr 7: 155.07 – 155.09 Mb Chr 7: 27.84 – 27.86 Mb
PubMed search [3] [4]
View/Edit Human View/Edit Mouse

5-Hydroxytryptamine (serotonin) receptor 5A, also known as HTR5A, is a protein that in humans is encoded by the HTR5A gene.[5][6]


The gene described in this record is a member of 5-hydroxytryptamine receptor family and encodes a multi-pass membrane protein that functions as a receptor for 5-hydroxytryptamine and couples to G proteins, negatively influencing cAMP levels via Gi and Go.[7] This protein has been shown to function in part through the regulation of intracellular Ca2+ mobilization.[5] The 5-HT5A receptor has been shown to be functional in a native expression system.[8]

Rodents have been shown to possess two functional 5-HT5 receptor subtypes, 5-HT5A and 5-HT5B,[9] however while humans possess a gene coding for the 5-HT5B subtype, its coding sequence is interrupted by stop codons, making the gene non-functional, and so only the 5-HT5A subtype is expressed in human brain.[10]

It also appears to serve as a presynaptic serotonin autoreceptor.[11]

Clinical significance[edit]

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has been implicated in a wide range of psychiatric conditions and also has vasoconstrictive and vasodilatory effects.[5]

Selective Ligands[edit]

Few highly selective ligands are commercially available for the 5-HT5A receptor. When selective activation of this receptor is desired in scientific research, the non-selective serotonin receptor agonist 5-Carboxamidotryptamine can be used in conjunction with selective antagonists for its other targets (principally 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT7). Research in this area is ongoing.[12][13]


  • Valerenic acid, a component of valerian, has been shown to act as a 5HT5A partial agonist.[14]
  • Another ligand that has been recently disclosed is shown below, claimed be a selective 5-HT5A agonist with Ki = 124 nM.[15]

DE19900637A1 5HT5A ligand.png


See also[edit]


  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000157219 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000039106 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ a b c "Entrez Gene: HTR5A 5-hydroxytryptamine (serotonin) receptor 5A". 
  6. ^ Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M (Dec 1994). "Cloning and characterisation of the human 5-HT5A serotonin receptor". FEBS Letters. 355 (3): 242–6. PMID 7988681. doi:10.1016/0014-5793(94)01209-1. 
  7. ^ Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE (Nov 1998). "The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells". European Journal of Pharmacology. 361 (2–3): 299–309. PMID 9865521. doi:10.1016/S0014-2999(98)00744-4. 
  8. ^ Goodfellow NM, Bailey CD, Lambe EK (Apr 2012). "The native serotonin 5-HT(5A) receptor: electrophysiological characterization in rodent cortex and 5-HT(1A)-mediated compensatory plasticity in the knock-out mouse". The Journal of Neuroscience. 32 (17): 5804–9. PMC 4644074Freely accessible. PMID 22539842. doi:10.1523/JNEUROSCI.4849-11.2012. 
  9. ^ Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat JL, Muscatelli F, Mattei MG, Hen R (Mar 1993). "Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization". Molecular Pharmacology. 43 (3): 313–9. PMID 8450829. 
  10. ^ Nelson DL (Feb 2004). "5-HT5 receptors". Current Drug Targets. CNS and Neurological Disorders. 3 (1): 53–8. PMID 14965244. doi:10.2174/1568007043482606. 
  11. ^ Thomas DR, Soffin EM, Roberts C, Kew JN, de la Flor RM, Dawson LA, Fry VA, Coggon SA, Faedo S, Hayes PD, Corbett DF, Davies CH, Hagan JJ (Sep 2006). "SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain". Neuropharmacology. 51 (3): 566–77. PMID 16846620. doi:10.1016/j.neuropharm.2006.04.019. 
  12. ^ Wesołowska A (2002). "In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors" (PDF). Polish Journal of Pharmacology. 54 (4): 327–41. PMID 12523486. 
  13. ^ Peters JU, Lübbers T, Alanine A, Kolczewski S, Blasco F, Steward L (Jan 2008). "Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration". Bioorganic & Medicinal Chemistry Letters. 18 (1): 262–6. PMID 18023344. doi:10.1016/j.bmcl.2007.10.078. 
  14. ^ Dietz BM, Mahady GB, Pauli GF, Farnsworth NR (Aug 2005). "Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro". Brain Research. Molecular Brain Research. 138 (2): 191–7. PMID 15921820. doi:10.1016/j.molbrainres.2005.04.009. 
  15. ^ Garcia-Ladona, Francisco Javier; Szabo, Laszlo; Steiner, Gerd; Hofmann, Hans-Peter (2004-06-15). "Use of 5-HT5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances". Patent US 6750221. 
  16. ^ a b c Yamazaki M, Okabe M, Yamamoto N, Yarimizu J, Harada K (2015). "Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats". J. Pharmacol. Sci. 127 (3): 362–9. PMID 25837935. doi:10.1016/j.jphs.2015.02.006. 
  17. ^ Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, Ni K, Matsuoka N (2014). "ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia". Eur Neuropsychopharmacol. 24 (10): 1698–708. PMID 25108314. doi:10.1016/j.euroneuro.2014.07.009. 
  18. ^ Wu J, Li Q, Bezprozvanny I (2008). "Evaluation of Dimebon in cellular model of Huntington's disease". Molecular Neurodegeneration. 3 (1): 15. PMC 2577671Freely accessible. PMID 18939977. doi:10.1186/1750-1326-3-15. 

Further reading[edit]

  • Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, Garnovskaya MN (2002). "Multiplicity of mechanisms of serotonin receptor signal transduction". Pharmacology & Therapeutics. 92 (2–3): 179–212. PMID 11916537. doi:10.1016/S0163-7258(01)00169-3. 
  • Thomas DR (Sep 2006). "5-ht5A receptors as a therapeutic target". Pharmacology & Therapeutics. 111 (3): 707–14. PMID 16516972. doi:10.1016/j.pharmthera.2005.12.006. 
  • Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M (Dec 1994). "Cloning and characterisation of the human 5-HT5A serotonin receptor". FEBS Letters. 355 (3): 242–6. PMID 7988681. doi:10.1016/0014-5793(94)01209-1. 
  • Schanen NC, Scherer SW, Tsui LC, Francke U (1997). "Assignment of the 5-hydroxytryptamine (serotonin) receptor 5A gene (HTR5A) to human chromosome band 7q36.1". Cytogenetics and Cell Genetics. 72 (2–3): 187–8. PMID 8978771. doi:10.1159/000134184. 
  • "Toward a complete human genome sequence". Genome Research. 8 (11): 1097–108. Nov 1998. PMID 9847074. doi:10.1101/gr.8.11.1097. 
  • Francken BJ, Josson K, Lijnen P, Jurzak M, Luyten WH, Leysen JE (May 2000). "Human 5-hydroxytryptamine(5A) receptors activate coexpressed G(i) and G(o) proteins in Spodoptera frugiperda 9 cells". Molecular Pharmacology. 57 (5): 1034–44. PMID 10779389. 
  • Marazziti D, Ori M, Nardini M, Rossi A, Nardi I, Cassano GB (2001). "mRNA expression of serotonin receptors of type 2C and 5A in human resting lymphocytes". Neuropsychobiology. 43 (3): 123–6. PMID 11287788. doi:10.1159/000054878. 
  • Iwata N, Ozaki N, Inada T, Goldman D (Mar 2001). "Association of a 5-HT(5A) receptor polymorphism, Pro15Ser, to schizophrenia". Molecular Psychiatry. 6 (2): 217–9. PMID 11317225. doi:10.1038/sj.mp.4000829. 
  • Grailhe R, Grabtree GW, Hen R (Apr 2001). "Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution". European Journal of Pharmacology. 418 (3): 157–67. PMID 11343685. doi:10.1016/S0014-2999(01)00933-5. 
  • Noda M, Yasuda S, Okada M, Higashida H, Shimada A, Iwata N, Ozaki N, Nishikawa K, Shirasawa S, Uchida M, Aoki S, Wada K (Jan 2003). "Recombinant human serotonin 5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways". Journal of Neurochemistry. 84 (2): 222–32. PMID 12558985. doi:10.1046/j.1471-4159.2003.01518.x. 
  • Khorana N, Smith C, Herrick-Davis K, Purohit A, Teitler M, Grella B, Dukat M, Glennon RA (Aug 2003). "Binding of tetrahydrocarboline derivatives at human 5-HT5A receptors". Journal of Medicinal Chemistry. 46 (18): 3930–7. PMID 12930153. doi:10.1021/jm030080s. 
  • Dietz BM, Mahady GB, Pauli GF, Farnsworth NR (Aug 2005). "Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro". Brain Research. Molecular Brain Research. 138 (2): 191–7. PMID 15921820. doi:10.1016/j.molbrainres.2005.04.009. 

External links[edit]

  • "5-ht5a". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. 
  • Human HTR5A genome location and HTR5A gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.